argenx NV ADR (ARGX)vsCue Biopharma (CUE)
ARGX
argenx NV ADR
$891.76
+1.05%
HEALTHCARE · Cap: $54.94B
CUE
Cue Biopharma
$21.16
+15.50%
HEALTHCARE · Cap: $123.79M
Smart Verdict
WallStSmart Research — data-driven comparison
argenx NV ADR generates 15610% more annual revenue ($5.92B vs $37.66M). ARGX leads profitability with a 31.7% profit margin vs 0.0%. ARGX earns a higher WallStSmart Score of 73/100 (B).
ARGX
Strong Buy73
out of 100
Grade: B
CUE
Avoid29
out of 100
Grade: F
Intrinsic Value Comparison
Multi-model valuation · Graham Formula
Margin of Safety
+67.5%
Fair Value
$2566.94
Current Price
$891.76
$1675.18 discount
Intrinsic value data unavailable for CUE.
Key Strengths & Concerns
Side-by-side fundamental analysis
Key Strengths
Every $100 of equity generates 31 in profit
Keeps 32 of every $100 in revenue as profit
Strong operational efficiency at 36.3%
Revenue surging 52.1% year-over-year
Earnings expanding 50.6% YoY
Conservative balance sheet, low leverage
Revenue surging 166.7% year-over-year
Areas to Watch
Premium valuation, high expectations priced in
Weak financial health signals
Trading at 165.8x book value
0.0% earnings growth
Smaller company, higher risk/reward
0.0% margin — thin
Trading at 48.1x book value
Comparative Analysis Report
WallStSmart ResearchBull Case : ARGX
The strongest argument for ARGX centers on Return on Equity, Profit Margin, Operating Margin. Profitability is solid with margins at 31.7% and operating margin at 36.3%. Revenue growth of 52.1% demonstrates continued momentum.
Bull Case : CUE
The strongest argument for CUE centers on Revenue Growth. Revenue growth of 166.7% demonstrates continued momentum.
Bear Case : ARGX
The primary concerns for ARGX are P/E Ratio, Piotroski F-Score, Price/Book.
Bear Case : CUE
The primary concerns for CUE are EPS Growth, Market Cap, Profit Margin. Debt-to-equity of 3.81 is elevated, increasing financial risk.
Key Dynamics to Monitor
ARGX profiles as a growth stock while CUE is a hypergrowth play — different risk/reward profiles.
CUE carries more volatility with a beta of 2.63 — expect wider price swings.
CUE is growing revenue faster at 166.7% — sustainability is the question.
ARGX generates stronger free cash flow (749M), providing more financial flexibility.
Bottom Line
ARGX scores higher overall (73/100 vs 29/100), backed by strong 31.7% margins and 52.1% revenue growth. Both earn "Strong Buy" and "Avoid" ratings respectively — the choice depends on your investment horizon and risk tolerance.
This analysis is generated from publicly available financial data. Not financial advice.
argenx NV ADR
HEALTHCARE · BIOTECHNOLOGY · USA
argenx SE, a clinical-phase biotechnology company, focuses on the development of antibody-based therapies for the treatment of autoimmune diseases, hematology and cancer. The company is headquartered in Breda, the Netherlands.
Cue Biopharma
HEALTHCARE · BIOTECHNOLOGY · USA
Cue Biopharma, Inc., a clinical-stage biopharmaceutical company, develops biological drugs for the selective modulation of the human immune system to treat a variety of cancers, chronic infectious diseases, and autoimmune disorders. The company is headquartered in Cambridge, Massachusetts.
Compare with Other BIOTECHNOLOGY Stocks
Want to dig deeper into these stocks?